Gardasil gets FDA’s quick review, for approval in women 27 to 45

The United States Food and Drug Administration will give Merck priority review to expand the Gardasil vaccine for use in women ages 27 to 45.

FDA officials announced today that they would make the decision in six months, as opposed to the agency’s typical 10-month review period.

Read the story by Reuters here.